ConductScience.org, home

Paper8740978

In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.

Cipolla B and 6 others. Urol Res, 1996. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide. Papers, record 8740978. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8740978

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.
PubMed
Journal
Urol Res
PubMed
Year
1996
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.34
iCite
Revised in PubMed
2019-09-14
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cipolla BB
2Blanchard YY
3Chamaillard LL
4Quemener VV
5Guillé FF
6Havouis RR
7Moulinoux JPJ P

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
PolyaminesMajor topic
Prostatic NeoplasmsMajor topic
Animals
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Dose-Response Relationship, Drug
Drug Synergism
Drug Therapy, Combination
Eflornithine
Lung Neoplasms
Male
Metronidazole
Neomycin
Oxidoreductases Acting on CH-NH Group Donors
Protein Synthesis Inhibitors
Putrescine
Rats
Rats, Inbred Strains
Survival Rate

Source PubMed

Download CSV of topics

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11942311The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation.J Urol1991https://conductscience.org/library/papers/1942311PubMed
27300587Red cell free polyamine concentrations in patients on maintenance hemodialysis.Life Sci1981https://conductscience.org/library/papers/7300587PubMed
3350276Polyamines in rapid growth and cancer.Biochim Biophys Acta1978https://conductscience.org/library/papers/350276PubMed
41444206Polyamine deprivation enhances antitumoral efficacy of chemotherapy.Anticancer Res1992https://conductscience.org/library/papers/1444206PubMed
53314999Prostate tumor progression and metastasis.Biochim Biophys Acta1987https://conductscience.org/library/papers/3314999PubMed
67041538Polyamines in mammalian tumors. Part I.Adv Cancer Res1981https://conductscience.org/library/papers/7041538PubMed
77040832Interconversion, catabolism and elimination of the polyamines.Med Biol1981https://conductscience.org/library/papers/7040832PubMed
83123052Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy.Cancer Res1988https://conductscience.org/library/papers/3123052PubMed
91700142Erythrocyte polyamine levels in human prostatic carcinoma.J Urol1990https://conductscience.org/library/papers/1700142PubMed
107689970Polyamines and prostatic carcinoma: clinical and therapeutic implications.Eur Urol1993https://conductscience.org/library/papers/7689970PubMed
113530115Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy.Anticancer Res1986https://conductscience.org/library/papers/3530115PubMed
122116224Endogenous and exogenous polyamines in support of tumor growth.Cancer Res1990https://conductscience.org/library/papers/2116224PubMed
132028560Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate.Urol Res1991https://conductscience.org/library/papers/2028560PubMed
147508520Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients.J Urol1994https://conductscience.org/library/papers/7508520PubMed
153118759Inhibition of polyamine oxidase improves the antitumoral effect of ornithine decarboxylase inhibitors.Anticancer Res1987https://conductscience.org/library/papers/3118759PubMed
162924329Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2924329PubMed
172018351Inhibition of the growth of U-251 human glioblastoma in nude mice by polyamine deprivation.Anticancer Res1991https://conductscience.org/library/papers/2018351PubMed
182495754The gastrointestinal tract as polyamine source for tumor growth.Anticancer Res1989https://conductscience.org/library/papers/2495754PubMed
196466732In vitro studies on the entry of polyamines into normal red blood cells.Biochimie1984https://conductscience.org/library/papers/6466732PubMed
203965702N-2,3-Butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase.J Med Chem1985https://conductscience.org/library/papers/3965702PubMed

See all 21 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8740978

GET https://conductscience.org/api/papers/v1/8740978/references?page=2